Roles
- Professor of Ophthalmology
-
Education & Training
Education
-
Research Interests
Early-onset and late-onset maculopathies particularly age-related macular degeneration
Genetics of AMD
Therapies for dry and wet AMD -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Shaping the Future of Eye Care
Ten Bascom Palmer Doctors Named to The Ophthalmologist Power List 2023
Bascom Palmer Celebrates 60th Anniversary
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 10 clinical trials.
-
HORIZON: A Phase II, Open-label, Outcomes-assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- Principal Investigator: Philip Rosenfeld
- Study Phase: Phase 2
- Enrollment Status: Closed
-
EXPLORE: A Phase II, Outcomes Assessor-masked, Multicentre, Randomised Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
- Principal Investigator: Philip Rosenfeld
- Study Phase: Phase 2
- Enrollment Status: Closed
-
The purpose of this study is to compare the ability to read a visual acuity chart with the circulation in the back of the eye. Visual acuity tests and scans of the back of the eye will be completed at each study visit.
- Principal Investigator: Philip Rosenfeld
- Study Phase: N/A
- Enrollment Status: Closed
-
A saliva sample will be collected from patients with geographic atrophy secondary to age-related macular degeneration to test for a specific gene. Patients with the gene will be added to a registry for future study participation.
- Principal Investigator: Philip Rosenfeld
- Study Phase: N/A
- Enrollment Status: Closed
-
A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Principal Investigator: Philip Rosenfeld
- Study Phase: Phase 3
- Enrollment Status: Not Accepting
-
Evaluate the choroidal vascular parameters associated with an ocular condition that affects choroidal perfusion, and if an intervention is performed, then evaluate the choroidal vascular parameters following the intervention that could affect the ocular circulation such as, but not limited to, carotid artery stenosis (CAS), Graves orbitopathy (GO), and carotid-cavernous sinus (CCF) fistulas using PLEX Elite SS-OCT angiography.
- Principal Investigator: Philip Rosenfeld
- Study Phase: N/A
- Enrollment Status: Closed
-
A Natural History Observation and Registry Study of Macular Telangiectasia Type 2.
- Principal Investigator: Philip Rosenfeld
- Study Phase: N/A
- Enrollment Status: Open
-
GT005, a recombinant adeno-associated viral serotype 2 (AAV2) vector encoding for human complement factor I, is currently being developed as a potential gene therapy for GA secondary to AMD. The overall objectives of the study are to evaluate the long-term safety and durability of GT005 in participants with GA secondary to AMD who have been treated in an antecedent study. Participants in this follow-up study will be evaluated for 3 years (a total duration of 5 years post-GT005 administration).
- Principal Investigator: Philip Rosenfeld
- Study Phase: TBD
- Enrollment Status: Not Accepting
-
Phase II, Multicenter, Open-label Safety Study of Bilateral NT-501 in Participants With Macular Telangiectasia Type 2
- Principal Investigator: Philip Rosenfeld
- Study Phase: Phase 2
- Enrollment Status: Closed
-
A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
- Principal Investigator: Philip Rosenfeld
- Study Phase: Phase 2
- Enrollment Status: Closed